Terminated PHASE2 INTERVENTIONAL 1-arm NCT00053014

S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia

S0125, A Phase II Study Of Chimerism-Mediated Immunotherapy (CMI) Using Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation In Older Patients With Acute Myeloid Leukemia (AML) In First Complete Remission (A BMT Study)

Sponsor: National Cancer Institute (NCI)

Conditions Leukemia

Interventions cyclosporine fludarabine mycophenolate mofetil peripheral blood stem cell transplantation radiation therapy therapeutic allogeneic lymphocytes

Updated 10 times since 2017 Last updated: Mar 5, 2015 Started: Apr 30, 2003 Primary completion: Jun 30, 2005 Completion: Jun 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Poor accrual

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

Other Leukemia trials with similar outcome

Browse all Leukemia trials

A PHASE2 clinical study on Leukemia, this trial is terminated or withdrawn. The trial is conducted by National Cancer Institute (NCI) and has accumulated 10 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
May 2023 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2023 — May 2023 [monthly]

Terminated PHASE2

▶ Show 5 earlier versions

Dec 2022 — Jan 2023 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2022 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Apr 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
SWOG Cancer Research Network

Data source: SWOG Cancer Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Albuquerque, United States , Amarillo, United States , Ann Arbor, United States , Atlanta, United States , Aurora, United States , Beech Grove, United States , Billings, United States , Boise, United States , Boston, United States and 47 more locations